Literature DB >> 27463801

NR5A1 Loss-of-Function Mutations Lead to 46,XY Partial Gonadal Dysgenesis Phenotype: Report of Three Novel Mutations.

Helena C Fabbri1, Juliana G Ribeiro de Andrade, Andréa T Maciel-Guerra, Gil Guerra-Júnior, Maricilda P de Mello.   

Abstract

Mutations in the NR5A1 gene, which encodes the steroidogenic factor 1 (SF1), are responsible for different phenotypes of disorders of sex development (DSD), such as bilateral anorchia and hypospadias. Furthermore, they can be associated with primary amenorrhea, premature ovarian failure, male infertility, adrenal tumors, and endometriosis. Direct sequencing of the 7 NR5A1 exons including ∼1,000 bp of the 5'-upstream and 3'-downstream regions and all intron-exon boundaries was performed in patients with DSD. Three different in silico tools were used to assess the consequences of a splice site mutation. As a result, 3 novel NR5A1 mutations were identified in 3 patients with 46,XY partial gonadal dysgenesis: p.Lys38* and p.Leu80Trpfs*8 lead to premature translation termination codons within the SF1 DNA-binding domain, and the intronic nucleotide substitution c.1138+1G>T at the intron 6 donor splice site is considered to modify correct splicing. We assume that the anomalous mRNA produced as a result of p.Lys38* and p.Leu80Trpfs*8 will be degraded by nonsense-mediated mRNA decay even before translation, leading to SF1 haploinsufficiency. The c.1138+1G>T mutation is expected to produce a truncated protein. Heterozygous SF1 loss-of-function mutations in these cases resulted in mild DSD manifestations, such as dysgenetic testes, spontaneous puberty, and preserved adrenal function.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27463801     DOI: 10.1159/000448013

Source DB:  PubMed          Journal:  Sex Dev        ISSN: 1661-5425            Impact factor:   1.824


  6 in total

Review 1.  Current Knowledge on Endometriosis Etiology: A Systematic Review of Literature.

Authors:  Lyudmila M Mikhaleva; Victor E Radzinsky; Mekan R Orazov; Tatyana N Khovanskaya; Anastasia V Sorokina; Sergey A Mikhalev; Snezhana V Volkova; Victoria B Shustova; Mikhail Y Sinelnikov
Journal:  Int J Womens Health       Date:  2021-06-01

Review 2.  Wide spectrum of NR5A1-related phenotypes in 46,XY and 46,XX individuals.

Authors:  Sorahia Domenice; Aline Zamboni Machado; Frederico Moraes Ferreira; Bruno Ferraz-de-Souza; Antonio Marcondes Lerario; Lin Lin; Mirian Yumie Nishi; Nathalia Lisboa Gomes; Thatiana Evelin da Silva; Rosana Barbosa Silva; Rafaela Vieira Correa; Luciana Ribeiro Montenegro; Amanda Narciso; Elaine Maria Frade Costa; John C Achermann; Berenice Bilharinho Mendonca
Journal:  Birth Defects Res C Embryo Today       Date:  2016-12

3.  A novel C-terminal truncating NR5A1 mutation in dizygotic twins.

Authors:  Atsushi Hattori; Hiroaki Zukeran; Maki Igarashi; Suzuka Toguchi; Yuji Toubaru; Takanobu Inoue; Yuko Katoh-Fukui; Maki Fukami
Journal:  Hum Genome Var       Date:  2017-03-16

4.  Phenotype and Molecular Characterizations of 30 Children From China With NR5A1 Mutations.

Authors:  Yanning Song; Lijun Fan; Chunxiu Gong
Journal:  Front Pharmacol       Date:  2018-10-30       Impact factor: 5.810

5.  Pubertal development in 46,XY patients with NR5A1 mutations.

Authors:  Isabel Mönig; Julia Schneidewind; Trine H Johannsen; Anders Juul; Ralf Werner; Ralf Lünstedt; Wiebke Birnbaum; Louise Marshall; Lutz Wünsch; Olaf Hiort
Journal:  Endocrine       Date:  2021-10-06       Impact factor: 3.633

6.  Functional characterization of novel NR5A1 variants reveals multiple complex roles in disorders of sex development.

Authors:  Gorjana Robevska; Jocelyn A van den Bergen; Thomas Ohnesorg; Stefanie Eggers; Chloe Hanna; Remko Hersmus; Elizabeth M Thompson; Anne Baxendale; Charles F Verge; Antony R Lafferty; Nanis S Marzuki; Ardy Santosa; Nurin A Listyasari; Stefan Riedl; Garry Warne; Leendert Looijenga; Sultana Faradz; Katie L Ayers; Andrew H Sinclair
Journal:  Hum Mutat       Date:  2017-11-02       Impact factor: 4.878

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.